Sanofi Jumps Into Radiopharmaceuticals, Paying €100M for Therapy That Could Rival a Novartis Drug

Sanofi is licensing a RadioMedix radiopharmaceutical in development for neuroendocrine tumors. The French pharmaceutical giant is responsible for global commercialization of the therapy, a potential competitor to the Novartis radiopharmaceutical Lutathera. The post Sanofi Jumps Into Radiopharmaceuticals, Paying €100M for Therapy That Could Rival a Novartis Drug appeared first on MedCity News.

Read More

How Wooster Community Hospital collected $3.8M in patient balances with Collections Optimization Manager

Could a more targeted approach to patient collections help providers maximize revenue? Wooster Community Hospital (WCH) has proof that it can – to the tune of a 7.75% boost in annual collections. In a recent webinar, Kristen Shoup, Wooster’s Revenue Cycle Director, and Judy Wirtz, Senior Analytics Consultant at Experian Health, shared their success in…

Read More